

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 03/037897 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 487/04**

**Christina, Portrude** [US/US]; 579 Shunpike Road,  
Chatham, NJ 07928 (US).

(21) International Application Number: PCT/EP02/12024

(22) International Filing Date: 28 October 2002 (28.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/340,923	29 October 2001 (29.10.2001)	US
60/361,655	5 March 2002 (05.03.2002)	US
60/379,365	9 May 2002 (09.05.2002)	US

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, Basel 4056 (CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1235 Viena (AT).

**Published:**

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BALL, Howard, Ashley** [GB/US]; 9 Shady Lane, Kendall Park, NJ 08824 (US). **COHEN, Pamela, Sarah** [US/US]; 131 Downey Drive, Tenafly, NJ 07670 (US). **LEE, Lucy** [US/US]; 33, Gordon Circle, Parsippany, NJ 07054 (US). **RAVERA,**

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN SOLID TUMOR DISEASES

(57) Abstract: Patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma or metastases of such solid tumor diseases are treated with a 7H-pyrrolo[2,3-d]pyrimidine derivative.



**WO 03/037897 A2**

### Use of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives in Solid Tumor Diseases

This invention relates to a method for the treatment of patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma comprising administering a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, in particular using an improved regimen for the administration of such 7H-pyrrolo[2,3-d]pyrimidine derivative.

7H-pyrrolo[2,3-d]pyrimidine derivatives useful for treating tumor diseases and other conditions are, e.g., disclosed in U.S. Patent No. 6,140,332, which is here incorporated by reference in its entirety. Such 7H-pyrrolo[2,3-d]pyrimidine derivatives are described in such patent to be useful for the treatment of benign or malignant tumours being capable of effecting tumour regression and of preventing the formation of tumour metastases and the growth of micrometastases. According to such patent such compounds can be used especially in the case of epidermal hyperproliferation (psoriasis), in the treatment of neoplasias of epithelial character, e.g. mammary carcinomas, and in leukaemias.

Furthermore, U.S. Patent No. 6,140,332 discloses that the 7H-pyrrolo[2,3-d]pyrimidine derivatives are administered in the case of an individual having a body weight of about 70 kg at a daily dose from approximately 0.1 grams to approximately 5 grams, preferably from about 0.5 grams to 2 grams. It is not suggested that the 7H-pyrrolo[2,3-d]pyrimidine derivative should be administered on alternate days.


Surprisingly, it was now found that 7H-pyrrolo[2,3-d]pyrimidine derivatives are suitable for the treatment of the solid tumor diseases mentioned herein. Thus, the present invention relates to the use of a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma or mesothelioma.

Furthermore, the present invention relates to a method for the treatment of patients suffering from a solid tumor disease selected from renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially NSCLC, tumors of the gastrointestinal tract, glioma and mesothelioma comprising administering a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, in particular using an improved regimen for the administration of such 7H-pyrrolo[2,3-d]pyrimidine derivative as described herein.

The present invention further relates to a method of inhibiting metastatic growth in a patient with a solid tumor disease as defined herein which comprises administering a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative or a pharmaceutically acceptable salt thereof, to the patient, in particular using an improved regimen for the administration of such 7H-pyrrolo[2,3-d]pyrimidine derivative as described herein.

In the present invention, the compound (R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine, or a pharmaceutically acceptable salt thereof, is the preferred 7H-pyrrolo[2,3-d]pyrimidine derivative, which compound is described in Example 39 of WO 97/02266. The compound is also known in the art as "PKI166" or "CGP 75166".

Another aspect of the present invention is the use of 7H-pyrrolo[2,3-d]pyrimidine derivative of formula I



wherein

R<sub>1</sub> and R<sub>2</sub> are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula R<sub>4</sub>-Y-(C=Z)- wherein R<sub>4</sub> is unsubstituted, mono- or disubstituted amino or a heterocyclic

radical, Y is either not present or lower alkyl and Z is oxygen, sulfur or imino, with the proviso that R<sub>1</sub> and R<sub>2</sub> are not both hydrogen; or

R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom to which they are attached form a heterocyclic radical;

R<sub>3</sub> is a heterocyclic radical or an unsubstituted or substituted aromatic radical;

G is C<sub>1</sub>-C<sub>7</sub>-alkylene, -C(=O)-, or C<sub>1</sub>-C<sub>6</sub>-alkylene-C(=O)- wherein the carbonyl group is attached to the NR<sub>1</sub>R<sub>2</sub> moiety;

Q is -NH- or -O-, with the proviso that Q is -O- if G is -C(=O)- or C<sub>1</sub>-C<sub>6</sub>-alkylene-C(=O)-; and

X is either not present or C<sub>1</sub>-C<sub>7</sub>-alkylene, with the proviso that a heterocyclic radical R<sub>3</sub> is bonded via a ring carbon atom if X is not present;

or a salt of the said compounds,

for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer.

A further aspect of the present invention is a method of inhibiting metastatic growth in a patient with a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer which comprises administering to the patient a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative of formula I wherein R<sub>1</sub> and R<sub>2</sub> are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula R<sub>4</sub>-Y-(C=Z)- wherein R<sub>4</sub> is unsubstituted, mono- or disubstituted amino or a heterocyclic radical, Y is either not present or lower alkyl and Z is oxygen, sulfur or imino, with the proviso that R<sub>1</sub> and R<sub>2</sub> are not both hydrogen; or R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom to which they are attached form a heterocyclic radical; R<sub>3</sub> is a heterocyclic radical or an unsubstituted or substituted aromatic radical; G is C<sub>1</sub>-C<sub>7</sub>-alkylene, -C(=O)-, or C<sub>1</sub>-C<sub>6</sub>-alkylene-C(=O)- wherein the carbonyl group is attached to the NR<sub>1</sub>R<sub>2</sub> moiety; Q is -NH- or -O-, with the proviso that Q is -O- if G is -C(=O)- or C<sub>1</sub>-C<sub>6</sub>-alkylene-C(=O)-; and X is either not present or C<sub>1</sub>-C<sub>7</sub>-alkylene, with the proviso that a heterocyclic radical R<sub>3</sub> is bonded via a ring carbon atom if X is not present; or a salt of the said compounds,

- 4 -

for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer.

The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated:

As used herein, the expression "week" means seven consecutive days. Thus, a three week period is twenty-one consecutive days starting on any day of the calendar week. The day that the first dose is given is considered to be the first day of the week. Any discussion using calendar weeks is intended to be for illustrative purposes only.

As used herein, the expression "mesothelioma" means a malignant tumor derived from mesothelial tissue (peritoneum, pleura, pericardium).

As used herein, the expression "glioma" preferably includes all primary intrinsic neoplasms of the brain and spinal cord, e.g. astrocytomas, ependymomas, neurocytomas or meningiomas.

The term "tumors of the gastrointestinal tract" as used herein, includes, but is not limited to esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, colorectal cancer and anorectal cancer.

As used herein, the expression "partial response" means a greater than or equal to 50 % reduction in measurable or evaluable disease in the absence of progression in any particular disease site.

As used herein, the expression "stable disease" means a less than 50 % decrease or less than 25 % increase in measurable or evaluable disease.

Asymmetric carbon atoms of a compound of formula I that are optionally present may exist in the (R), (S) or (R,S) configuration, preferably in the (R) or (S) configuration. Substituents at a double bond or a ring may be present in cis- (= Z-) or trans (= E-) form. The compounds may thus be present as mixtures of isomers or preferably as pure isomers.

Preferably alkyl contains up to 20 carbon atoms and is most preferably lower alkyl.

The prefix "lower" denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either unbranched or branched with single or multiple branching.

Lower alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl or n-heptyl.

Alkyl  $R_1$  and  $R_2$  independently of each other are preferably methyl, ethyl, isopropyl or tert-butyl, especially methyl or ethyl.

Lower alkyl Y is preferably methyl, ethyl or propyl.

Lower alkoxy is for example ethoxy or methoxy, especially methoxy.

Substituted alkyl is preferably lower alkyl as defined above where one or more, preferably one, substituents may be present, such as e.g. amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower alkylthio, halogen or a heterocyclic radical.

Substituted alkyl  $R_1$  and  $R_2$  are independently of each other preferably hydroxy-lower alkyl, N,N-di-lower alkylamino-lower alkyl or morpholinyl-lower alkyl.

Preferably unsubstituted or substituted cycloalkyl  $R_1$  or  $R_2$  contains from 3 up to 20 carbon atoms and is especially unsubstituted or also substituted  $C_3$ - $C_6$  cycloalkyl wherein the substituents are selected from e.g. unsubstituted or substituted lower alkyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower alkylthio, halogen or a heterocyclic radical.

Mono- or disubstituted amino is amino substituted by one or two radicals selected independently of one another from e.g. unsubstituted or substituted lower alkyl.

Disubstituted amino  $R_4$  is preferably N,N-di-lower alkylamino, especially N,N-dimethylamino or N,N-diethylamino.

A heterocyclic radical contains especially up to 20 carbon atoms and is preferably a saturated or unsaturated monocyclic radical having from 4 or 8 ring members and from 1 to 3 heteroatoms which are preferably selected from nitrogen, oxygen and sulfur, or a bi- or tri-cyclic radical wherein, for example, one or two carbocyclic radicals, such as e.g. benzene radicals, are annellated (fused) to the mentioned monocyclic radical. If a heterocyclic radical contains a fused carbocyclic radical then the heterocyclic radical may also be attached to the rest of the molecule of formula I via a ring atom of the fused carbocyclic radical. The heterocyclic radical (including the fused carbocyclic radical(s) if present) is optionally substituted by one or more, preferably by one or two, radicals such as e.g. unsubstituted or substituted lower alkyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower alkoxy-carbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower alkylthio, or halogen.

Most preferably a heterocyclic radical is pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl, morpholinyl, tetrahydropyranyl, pyridyl, pyridyl substituted by hydroxy or lower alkoxy, or benzodioxolyl, especially pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl or morpholinyl.

A heterocyclic radical  $R_1$  or  $R_2$  is as defined above for a heterocyclic radical with the proviso that it is bonded to the rest of the molecule of formula I via a ring carbon atom. Preferably a heterocyclic radical  $R_1$  or  $R_2$  is lower alkyl-piperazinyl or especially preferred tetrahydropyranyl. If one of the two radicals  $R_1$  and  $R_2$  represents a heterocyclic radical, the other is preferably hydrogen.

- 7 -

A heterocyclic radical  $R_3$  is as defined above for a heterocyclic radical with the proviso that it is bonded to Q via a ring carbon atom if X is not present. Preferably a heterocyclic radical  $R_3$  is benzodioxolyl, pyridyl substituted by hydroxy or lower alkoxy, or especially preferred indolyl substituted by halogen and lower alkyl. If  $R_3$  is pyridyl substituted by hydroxy then the hydroxy group is preferably attached to a ring carbon atom adjacent to the ring nitrogen atom.

A heterocyclic radical  $R_4$  is as defined above for a heterocyclic radical and is preferably pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, morpholinyl or pyridyl.

If  $R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical, the heterocyclic radical is as defined above for a heterocyclic radical and represents preferably pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl or morpholinyl.

An unsubstituted or substituted aromatic radical  $R_3$  has up to 20 carbon atoms and is unsubstituted or substituted, for example in each case unsubstituted or substituted phenyl. Preferably an unsubstituted aromatic radical  $R_3$  is phenyl. A substituted aromatic radical  $R_3$  is preferably phenyl substituted by one or more substituents selected independently of one another from the group consisting of unsubstituted or substituted lower alkyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower alkoxy-carbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower alkylthio and halogen. Most preferably a substituted aromatic radical  $R_3$  is phenyl substituted by one or more radicals selected independently of one another from the group consisting of lower alkyl, amino, hydroxy, lower alkoxy, halogen and benzyloxy.

Halogen is primarily fluoro, chloro, bromo or iodo, especially fluoro, chloro or bromo.

$C_1$ - $C_7$ -alkylene may be branched or unbranched and is in particular  $C_1$ - $C_3$ -alkylene.

$C_1$ - $C_7$ -alkylene G is preferably  $C_1$ - $C_3$ -alkylene, most preferably methylene ( $-CH_2-$ ).



- 8 -

If G is not C<sub>1</sub>-C<sub>7</sub>-alkylene it preferably represents -C(=O)-.

C<sub>1</sub>-C<sub>7</sub>-alkylene X is preferably C<sub>1</sub>-C<sub>3</sub>-alkylene, most preferably methylene (-CH<sub>2</sub>-) or ethan-1,1-diyl (-CH(CH<sub>3</sub>)-).

Q is preferably -NH-.

Z is preferably oxygen or sulfur, most preferably oxygen.

Salts are especially the pharmaceutically acceptable salts of compounds of formula I.

Special preference is given to a compound of formula I, wherein

R<sub>1</sub> and R<sub>2</sub> are each independently of the other hydrogen, lower alkyl, hydroxy-lower alkyl, or a radical of the formula R<sub>4</sub>-Y-(C=Z)- wherein R<sub>4</sub> is di-lower alkylamino, pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, morpholinyl or pyridyl, Y is either not present or lower alkyl and Z is oxygen, with the proviso that R<sub>1</sub> and R<sub>2</sub> are not both hydrogen; or

R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom to which they are attached form a radical selected from the group consisting of pyrrolidinyl, piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl and morpholinyl;

R<sub>3</sub> is phenyl, benzodioxolyl, pyridyl substituted by hydroxy or lower alkoxy, or phenyl substituted by one or more radicals selected independently of one another from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen and benzyloxy;

G is -CH<sub>2</sub>-;


Q is -NH-; and

X is either not present, -CH<sub>2</sub>- or -CH(CH<sub>3</sub>)-, with the proviso that substituted pyridyl R<sub>3</sub> is bonded via a ring carbon atom if X is not present; or a salt thereof.


The compounds of formula I or salts thereof are prepared in accordance with processes known per se (see also EP 682 027, WO 97/02266, WO 97/27199 and WO 98/07726), though not previously described for the manufacture of the compounds of the formula I, especially whereby in order to prepare a compound of formula I, wherein G is C<sub>1</sub>-C<sub>7</sub>-alkylene and wherein R<sub>1</sub> and R<sub>2</sub> are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, or a heterocyclic radical bonded via a ring carbon atom, with

- 9 -

the proviso that  $R_1$  and  $R_2$  are not both hydrogen, or wherein  $R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical, a compound of the formula II



wherein Hal is halogen, G is  $C_1$ - $C_7$ -alkylene and  $R_3$ , Q and X have the meanings as defined for a compound of formula I, is reacted with a compound of the formula III



wherein  $R_1$  and  $R_2$  are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, or a heterocyclic radical bonded via a ring carbon atom, with the proviso that  $R_1$  and  $R_2$  are not both hydrogen, or wherein  $R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical;

whereby functional groups which are present in the starting compounds of processes a) to d) and are not intended to take part in the reaction, are present in protected form if necessary, and protecting groups that are present are cleaved, whereby the said starting compounds may also exist in the form of salts provided that a salt-forming group is present and a reaction in salt form is possible;

and, if so desired, a compound of formula I thus obtained is converted into another compound of formula I, a free compound of formula I is converted into a salt, an obtained salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.

Description of the process variants:

The reaction between a compound of formula II and a compound of formula III preferably takes place in a suitable inert solvent, especially *N,N*-dimethylformamide, in the presence of a base such as potassium carbonate, at temperatures from room temperature (RT) to 100 °C. Alternatively, the reaction between a compound of formula II and a compound of formula III takes place in a suitable solvent, e.g. lower alcohols, such as ethanol, in the presence of for example a suitable catalyst such as NaI, preferably at the reflux temperature of the solvent employed. In a compound of formula II, Hal is preferably chloro.

Additional process steps

In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more protecting groups. The protecting groups are then wholly or partly removed according to one of the known methods.

Protecting groups, and the manner in which they are introduced and removed are described, for example, in "Protective Groups in Organic Chemistry", Plenum Press, London, New York 1973, and in "Methoden der organischen Chemie", Houben-Weyl, 4th edition, Vol. 15/1, Georg-Thieme-Verlag, Stuttgart 1974 and in Theodora W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, New York 1981. A characteristic of protecting groups is that they can be removed readily, i.e. without the occurrence of undesired secondary reactions, for example by solvolysis, reduction, photolysis or alternatively under physiological conditions.

The end products of formula I may however also contain substituents that can also be used as protecting groups in starting materials for the preparation of other end products of formula I. Thus, within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of formula I is designated a "protecting group", unless the context indicates otherwise.

General process conditions

All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of


solvents or diluents, preferably those that are inert to the reagents used and able to dissolve them, in the absence or presence of catalysts, condensing agents or neutralising agents, for example ion exchangers, typically cation exchangers, for example in the  $H^+$  form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from  $-100\text{ }^{\circ}\text{C}$  to about  $190\text{ }^{\circ}\text{C}$ , preferably from about  $-80\text{ }^{\circ}\text{C}$  to about  $150\text{ }^{\circ}\text{C}$ , for example at  $-80$  to  $-60\text{ }^{\circ}\text{C}$ , at RT, at  $-20$  to  $40\text{ }^{\circ}\text{C}$ , at  $0$  to  $100\text{ }^{\circ}\text{C}$  or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, if need be under pressure, and/or in an inert, for example an argon or nitrogen, atmosphere.

#### Starting materials

The starting materials used in the above described processes a) to b) are known, capable of being prepared according to known processes (see also EP 682 027, WO 97/02266, WO 97/27199 and WO 98/07726), or commercially obtainable; in particular, they can be prepared using processes as described in the Examples.

In the preparation of starting materials, existing functional groups which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the Examples. Where the term starting materials is used hereinbefore and hereinafter, the salts thereof are always included, insofar as reasonable and possible.


A compound of formula II can be prepared for example by reacting a compound of formula VII



wherein G is  $C_1$ - $C_7$ -alkylene and  $R_3$ , Q and X have the meanings as defined for a compound of formula I, with e.g. thionyl halogenide, preferably thionyl chloride, in the presence or


absence of pyridine, in an inert solvent, for example toluene or in a 1:1 mixture of acetonitrile and dioxane, preferably at  $-10$  to  $0$  °C or at RT.

A compound of formula VII can be prepared for example by reacting a compound of formula VIII



wherein  $R_5$  is lower alkyl, especially methyl or ethyl, and  $R_3$ , Q and X have the meanings as defined for a compound of formula I, with lithium aluminium hydride, in an inert solvent, especially ethers, e.g. cyclic ethers such as tetrahydrofuran, preferably at the reflux temperature of the solvent employed. Alternatively, a compound of formula VII may be prepared by reacting a compound of formula VIII with diisobutyl-aluminium hydride, in an inert solvent, for example in tetrahydrofuran or in a 1:1 mixture of dichloromethane and dioxane, preferably at RT.

A compound of formula VIII wherein Q is -NH- can be prepared for example by reacting a compound of formula IX



wherein Hal is halogen, preferably chloro, and  $R_5$  is as defined above for a compound of formula VIII, with a compound of the formula  $H_2N-X-R_3$ , wherein  $R_3$  and X have the meanings as defined for a compound of formula I, (i) in a suitable solvent such as alcohols,

especially lower alcohols such as *n*-butanol, preferably at the boiling temperature of the solvent employed or (ii) under catalytic conditions.

A compound of formula VIII wherein Q is -O- can be prepared for example by reacting a compound of formula IX, which is preferably N-protected in the pyrrolo-pyrimidine moiety, with a compound of the formula HO-X-R<sub>3</sub>, wherein R<sub>3</sub> and X have the meanings as defined for a compound of formula I, in a suitable inert solvent such as *N,N*-dimethylformamide and in the presence of a base such as potassium carbonate, at elevated temperatures, preferably at around 100 °C.

Alternatively, the carboxylic acid ester of a compound of formula IX may first be reduced to the corresponding alcohol, e.g. under conditions described above for the preparation of a compound of formula VII, and then either be reacted with a compound of the formula H<sub>2</sub>N-X-R<sub>3</sub>, e.g. under conditions described above for the preparation of a compound of formula VIII wherein Q is -NH-, or be reacted with a compound of the formula HO-X-R<sub>3</sub>, e.g. under conditions described above for the preparation of a compound of formula VIII wherein Q is -O-.

A compound of formula I, or a pharmaceutically acceptable salt thereof, can be used in pharmaceutical compositions known as such. Compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred. The compositions contain the active ingredient alone or, preferably, together with a pharmaceutically acceptable carrier. The dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration. The pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 20% to approximately 90% active ingredient and forms that are not of single-dose type comprising in the preferred embodiment from approximately 5% to approximately 20% active ingredient. Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories or capsules. Examples are capsules containing from about 0.05 g to about 1.0 g of active substance.

The pharmaceutical compositions of the present invention are prepared in a manner known *per se*, for example by means of conventional mixing, granulating, coating, dissolving or lyophilising processes.

The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.

In one preferred embodiment of the invention, the solid tumor disease to be treated is renal cell cancer. In another preferred embodiment of the invention, the solid tumor disease to be treated is NSCLC. In a further preferred embodiment of the invention, the solid tumor disease to be treated is selected from skin squamous cell carcinoma and head and neck squamous cell carcinoma. In another preferred embodiment of the invention, the solid tumor disease is anorectal cancer, especially anorectal adenocarcinoma and squamous cell carcinoma of the anal canal and margin and metastasis thereof.

In one embodiment the present invention relates to a treatment regimen whereby the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered to the human subject less frequently than on a daily basis. In particular, the present invention relates to a treatment regimen whereby over at least a three week period, the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered on only about 40% to about 71% of the days. In such embodiment, specifically, the present invention relates to a method of treating a human subject with a 7H-pyrrolo[2,3-d]pyrimidine derivative, which comprises administering such pyrimidine derivative to the human subject from three to five times in each seven day period for a period of three weeks or longer, more specifically, three or four times a week on alternate days for a period of three weeks or longer. In a specific embodiment, the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered three times each week on alternate days, for example, on Monday, Wednesday and Friday of each week, for at least three weeks. Thus, the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered every other day until three doses are given and the next dose is administered at the beginning of the following week. Preferably, such dosage regimen is carried out through at least four or more weeks, for example 4, 5, 6, 7 or 8 weeks. Alternatively, the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered daily for a period of one to three weeks,

e.g. two weeks, followed by a period of one to three weeks, e.g. two weeks without administering the compound to the patient.

Thus, the present invention relates especially to a method of treating a solid tumor disease as defined herein, which comprises administering a pharmaceutically effective amount of (R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine, or a salt thereof, to a human subject, preferably three or four times a week on alternate days, more preferably three times a week on alternate days, for a period of three weeks or longer.

The inventive dosage regimen applies to the use of 7H-pyrrolo[2,3-d]pyrimidine derivative, for example, PKI166, alone, or as part of a combination treatment therapy wherein it is co-administered with one or more additional pharmaceutical products useful for treating tumors, especially cancerous tumors. For purposes of this application co-administered means that the patient is treated with both drugs according to the proper schedule for each, but not necessarily that both drugs are administered together at the same time. Thus, the 7H-pyrrolo[2,3-d]pyrimidine derivative, may be administered alone or in combination with other anticancer agents, e.g. in accordance with the present inventive dosage regimen.

The 7H-pyrrolo[2,3-d]pyrimidine derivative is advantageously administered to the human subject at a pharmaceutically effective dosage in the range of from about 50 mg to about 2000 mg on days when the 7H-pyrrolo[2,3-d]pyrimidine derivative is administered. When PKI166 is employed, the preferred effective dose is in the range from about 50 mg to about 2000 mg, for example, about 450 mg to about 1500 mg doses or about 500 mg to about 1200 mg doses.

The 7H-pyrrolo[2,3-d]pyrimidine derivative is administered to the subject by methods known in the art for administering pharmaceutical products, for example, orally, rectally or parenterally, preferably orally as a tablet or capsule formulation. Especially, the 7H-pyrrolo[2,3-d]pyrimidine derivative can be administered as described in WO 97/02266.

The effect of a 7H-pyrrolo[2,3-d]pyrimidine derivative against the tumor types mentioned herein can be demonstrated, e.g., in suitable tumor models utilising cells lines, e.g. models utilising the cell lines NCI-H529 SCC (lung) or orthotopic 253J B-V (bladder).



The following Examples illustrate the invention described above; they are not, however, intended to limit the scope of the invention in any way. The beneficial effects of the 7H-pyrrolo[2,3-d]pyrimidine derivatives can also be determined by other test models known as such to the person skilled in the pertinent art.

## Examples

### Example 1: {6-[4-(4-Methyl-piperazin-1-yl)methyl]-phenyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-ethyl)-amine

A mixture of 10.8 g (30 mmol) [6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-ethyl)-amine in 450 ml DMF is treated with 6.8 ml (63 mmol) *N*-methyl-piperazine and 20.7 g (150 mmol) anhydrous potassium carbonate and the mixture heated to 65 °C for 1 hour. The reaction mixture is cooled and the inorganic salts removed by filtration (Hyflo Super Cel®; Fluka, Buchs, Switzerland). The DMF is evaporated under reduced pressure and the residue purified through flash chromatography using first dichloromethane/ethanol 9:1 and then dichloromethane/ethanol 9:1 plus 1% conc. ammonia. Crystallization of the pure fractions from THF (20 ml) and hexanes (80 ml) gives the title compound; m.p. 248-250 °C; MS-ES<sup>+</sup>: (M+H)<sup>+</sup> = 427.

### Step 1.1: 4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic acid ethyl ester

1.8 g (6 mmol) 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl ester (WO 97/02266) are suspended in 40 ml *n*-butanol and treated with 1.5 ml (12 mmol) (*R*)-phenethylamine. The mixture is heated to 145 °C under stirring. After 3 h a clear brown solution is obtained which is treated with a second portion of (*R*)-phenethylamine (0.75 ml, 6 mmol). After stirring for additional 2 h the reaction mixture is cooled in an ice bath and the title compound filtered and washed with cold *n*-butanol and ether; m.p. 288-290 °C.

### Step 1.2: {4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanol

570 mg (15 mmol) lithium aluminum hydride are suspended in 150 ml dry THF at RT. 1.23 g (3 mmol) 4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic acid ethyl ester are added and the mixture heated to reflux for 1 h. The mixture is cooled in an ice bath and treated sequentially with water (0.57 ml), 15% sodium hydroxide solution (0.57 ml) and water (1.71 ml). The solid aluminum complex is removed by filtration (Hyflo Super Cel®;

Fluka, Buchs, Switzerland), the filtrate dried over sodium sulfate evaporated. The residue is suspended in water, filtered and dried to give the title compound; m.p. > 300 °C;  $R_f$  (dichloromethane/ethanol 9:1 plus 1% conc. ammonia) = 0.43.

Step 1.3: [6-(4-Chloromethyl-phenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-((*R*)-1-phenyl-ethyl)-amine

A solution of thionyl chloride (25.7 ml, 0.328 mol) in 180 ml of toluene is cooled to -10 °C. Solid {4-[4-((*R*)-1-phenyl-ethylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-phenyl}-methanol (11.3 g, 0.0328 mol) is added in 8 portions over a range of 1 h. The temperature is then increased slowly to 0 °C and the mixture stirred for 2 h. The cold reaction mixture is filtered and the solid washed with toluene and ether. The crude product is suspended in water and treated with saturated sodium bicarbonate solution until the mixture turns basic. The mixture is stirred well for about 10 min and filtered. The solid is thoroughly washed with water and dried under reduced pressure to give the title compound; m.p. > 320 °C;  $R_f$  (dichloromethane/ethanol 9:1) = 0.46.

Examples 2 – 10:

The following Examples are synthesized from [6-(4-chloromethyl-phenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-((*R*)-1-phenyl-ethyl)-amine using an analogous procedure described in Example 1:

Example	Name	m.p. [°C]
2	[6-(4-Diethylaminomethyl-phenyl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	246-248
3	{6-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenyl]-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	245-247
4	(( <i>R</i> )-1-Phenyl-ethyl)-[6-(4-pyrrolidin-1-ylmethyl-phenyl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-amine	254-256
5	[6-(4-Dimethylaminomethyl-phenyl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	241-243
6	(( <i>R</i> )-1-Phenyl-ethyl)-[6-(4-piperidin-1-ylmethyl-phenyl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-amine	246-248
7	[6-(4-Morpholin-4-ylmethyl-phenyl)-7 <i>H</i> -pyrrolo[2,3-	263-265

	<i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	
8	{6-[4-(3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	208-210
9	(6-{4-[(2-Morpholin-4-yl-ethylamino)-methyl]-phenyl}-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl]-(( <i>R</i> )-1-phenyl-ethyl)-amine	222-224
10	(( <i>R</i> )-1-Phenyl-ethyl)-(6-{4-[(tetrahydro-pyran-4-ylamino)-methyl]-phenyl}-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-4-yl)-amine	253-255


Example 11: A human patient suffering from renal cell cancer is treated for a period of 16 weeks in 4 cycles consisting of administration of 600 mg of PKI166 daily for two weeks followed by 2 weeks without administering the drug. During such 16 weeks a stable disease is observed.

Example 12: A human patient suffering from renal cell cancer is treated for a period of 16 weeks with 400 mg of PKI166 on Monday, Wednesday and Friday of each week. During such 16 weeks a stable disease is observed.

Example 13: A human patient suffering from NSCLC is treated for a period of 8 weeks with 450 mg/day of PKI166 except on day 2, 16 and 30 on which days no drug is applied. After such treatment a partial response is observed.

WHAT IS CLAIMED:

1. The use of a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma or mesothelioma.
2. The use according to claim 1 wherein the 7H-pyrrolo[2,3-d]pyrimidine derivative is (R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine.
3. The use of a 7H-pyrrolo[2,3-d]pyrimidine derivative of formula I




wherein

- $R_1$  and  $R_2$  are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula  $R_4-Y-(C=Z)-$  wherein  $R_4$  is unsubstituted, mono- or disubstituted amino or a heterocyclic radical,  $Y$  is either not present or lower alkyl and  $Z$  is oxygen, sulfur or imino, with the proviso that  $R_1$  and  $R_2$  are not both hydrogen; or
- $R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical;
- $R_3$  is a heterocyclic radical or an unsubstituted or substituted aromatic radical;
- $G$  is  $C_1-C_7$ -alkylene,  $-C(=O)-$ , or  $C_1-C_6$ -alkylene- $C(=O)-$  wherein the carbonyl group is attached to the  $NR_1R_2$  moiety;
- $Q$  is  $-NH-$  or  $-O-$ , with the proviso that  $Q$  is  $-O-$  if  $G$  is  $-C(=O)-$  or  $C_1-C_6$ -alkylene- $C(=O)-$ ; and

X is either not present or C<sub>1</sub>-C<sub>7</sub>-alkylene, with the proviso that a heterocyclic radical R<sub>3</sub> is bonded via a ring carbon atom if X is not present;  
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer.

4. A method for the treatment of patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma comprising administering a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, to the patient.
5. The method of claim 4 which comprises administering the 7H-pyrrolo[2,3-d]pyrimidine derivative, or a salt thereof, to the human subject over at least a three week time period on only about 40% to about 71% of the days in the time period.
6. The method of claim 4 which comprises administering the 7H-pyrrolo[2,3-d]pyrimidine derivative, or a salt thereof, to the human subject three or four times a week on alternate days for a period of three weeks or longer.
7. The method of claim 4 wherein the pharmaceutically effective dose is in the range from about 50 mg to about 2000 mg.
8. A method for the treatment of patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer, comprising administering to the patient a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative of formula I

- 21 -



wherein

$R_1$  and  $R_2$  are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula  $R_4-Y-(C=Z)-$  wherein  $R_4$  is unsubstituted, mono- or disubstituted amino or a heterocyclic radical,  $Y$  is either not present or lower alkyl and  $Z$  is oxygen, sulfur or imino, with the proviso that  $R_1$  and  $R_2$  are not both hydrogen; or

$R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical;

$R_3$  is a heterocyclic radical or an unsubstituted or substituted aromatic radical;

$G$  is  $C_1$ - $C_7$ -alkylene,  $-C(=O)-$ , or  $C_1$ - $C_6$ -alkylene- $C(=O)-$  wherein the carbonyl group is attached to the  $NR_1R_2$  moiety;

$Q$  is  $-NH-$  or  $-O-$ , with the proviso that  $Q$  is  $-O-$  if  $G$  is  $-C(=O)-$  or  $C_1$ - $C_6$ -alkylene- $C(=O)-$ ; and

$X$  is either not present or  $C_1$ - $C_7$ -alkylene, with the proviso that a heterocyclic radical  $R_3$  is bonded via a ring carbon atom if  $X$  is not present;


or a pharmaceutically acceptable salt of said compound.

9. A method of inhibiting metastatic growth in a patient with a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma which comprises administering a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative, or a pharmaceutically acceptable salt thereof, to the patient.

10. The method of claim 9 which comprises administering the 7H-pyrrolo[2,3-d]pyrimidine derivative, or a salt thereof, to the human subject over at least a three week time period on only about 40% to about 71% of the days in the time period.

- 22 -

11. The method of claim 9 which comprises administering the 7H-pyrrolo[2,3-d]pyrimidine derivative, or a salt thereof, to the human subject three or four times a week on alternate days for a period of three weeks or longer.
12. The method of claim 9 wherein the pharmaceutically effective dose is in the range from about 50 mg to about 2000 mg.
13. The method of claim 9 wherein the 7H-pyrrolo[2,3-d]pyrimidine derivative is (R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine, or a pharmaceutically acceptable salt thereof.
14. A method of inhibiting metastatic growth in a patient with a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer which comprises administering to the patient a pharmaceutically effective amount of a 7H-pyrrolo[2,3-d]pyrimidine derivative of formula I



wherein

- $R_1$  and  $R_2$  are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula  $R_4-Y-(C=Z)-$  wherein  $R_4$  is unsubstituted, mono- or disubstituted amino or a heterocyclic radical,  $Y$  is either not present or lower alkyl and  $Z$  is oxygen, sulfur or imino, with the proviso that  $R_1$  and  $R_2$  are not both hydrogen; or
- $R_1$  and  $R_2$  together with the nitrogen atom to which they are attached form a heterocyclic radical;

- 23 -

$R_3$  is a heterocyclic radical or an unsubstituted or substituted aromatic radical;

G is  $C_1$ - $C_7$ -alkylene,  $-C(=O)-$ , or  $C_1$ - $C_6$ -alkylene- $C(=O)-$  wherein the carbonyl group is attached to the  $NR_1R_2$  moiety;

Q is  $-NH-$  or  $-O-$ , with the proviso that Q is  $-O-$  if G is  $-C(=O)-$  or  $C_1$ - $C_6$ -alkylene- $C(=O)-$ ; and

X is either not present or  $C_1$ - $C_7$ -alkylene, with the proviso that a heterocyclic radical  $R_3$  is bonded via a ring carbon atom if X is not present;

or a salt of the said compounds,

for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors and large-bowel tumors such as polyps of the colon and rectum, and anorectal cancer.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 03/037897 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/519**

**Christina, Portrude** [US/US]; 579 Shunpike Road,  
Chatham, NJ 07928 (US).

(21) International Application Number: PCT/EP02/12024

(74) **Agent: GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 28 October 2002 (28.10.2002)

(25) Filing Language: English

(81) **Designated States (national)**: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) **Priority Data**:  
60/340,923 29 October 2001 (29.10.2001) US  
60/361,655 5 March 2002 (05.03.2002) US  
60/379,365 9 May 2002 (09.05.2002) US

(84) **Designated States (regional)**: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(71) **Applicant (for all designated States except AT, US): NOVARTIS AG** [CH/CH]; Lichtstrasse 35, Basel 4056 (CH).

(71) **Applicant (for AT only): NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1235 Viena (AT).

**Published:**  
— with international search report

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): BALL, Howard, Ashley** [GB/US]; 9 Shady Lane, Kendall Park, NJ 08824 (US). **COHEN, Pamela, Sarah** [US/US]; 131 Downey Drive, Tenafly, NJ 07670 (US). **LEE, Lucy** [US/US]; 33, Gordon Circle, Parsippany, NJ 07054 (US). **RAVERA,**

(88) **Date of publication of the international search report:**  
18 September 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) **Title:** USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN THE TREATMENT OF SOLID TUMOR DISEASES

(57) **Abstract:** Patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma or metastases of such solid tumor diseases are treated with a 7H-pyrrolo[2,3-d]pyrimidine derivative.



WO 03/037897 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12024

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/519

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, PHARMAPROJECTS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 02266 A (CIBA GEIGY AG ;TRAXLER PETER (CH); BOLD GUIDO (CH); BRILL WOLFGANG) 23 January 1997 (1997-01-23) cited in the application page 1 -page 2 claims 1,12-15 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## ° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

17 March 2003

Date of mailing of the international search report

21. 05. 2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Langer, O

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12024

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRUNS CHRISTIANE J ET AL: "Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma." CANCER RESEARCH, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2926-2935, XP002232783 ISSN: 0008-5472 abstract tables 1-3	1
X	--- SOLORZANO, CARMEN C. ET AL: "Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma" CLINICAL CANCER RESEARCH (2001), 7(8), 2563-2572, XP002232784 abstract	1
Y	---	5,6,10, 11
X	WO 01 32155 A (BUNDRED NIGEL JAMES ;UNIV MANCHESTER (GB)) 10 May 2001 (2001-05-10) page 2, line 7 -page 3, line 28	1,2,4-7, 9-13
X	--- CARAVATTI G ET AL: "PYRROLO[2,3-]PYRIMIDINE AND PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF THE EGF RECEPTOR TYROSINE KINASE" ACS SYMPOSIUM SERIES, WASHINGTON, DC, US, vol. 796, 2001, pages 231-244, XP009002867 ISSN: 0097-6156 abstract page 233, paragraph 2 -page 234, paragraph 1 page 234, paragraph 3 page 239, paragraph 3 - paragraph 4 tables 3,5,6 figure 5	1
Y	---	2,4-7, 9-13
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12024

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WOODBURN J R: "THE EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS INHIBITORS IN CANCER THERAPY"            PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB,            vol. 82, no. 2/3, 1999, pages 241-250, XP000965337            ISSN: 0163-7258            page 241, left-hand column, paragraph 1            page 242, left-hand column, paragraph 2 - paragraph 4            page 243, right-hand column, paragraph 2            page 244, right-hand column, paragraph 3</p> <p>---</p>	2,4-7, 9-13
Y	<p>KELLOFF G J ET AL: "EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS AS POTENTIAL CANCER CHEMOPREVENTIVES"            CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH., US,            vol. 5, no. 8, August 1996 (1996-08), pages 657-666, XP000980248            ISSN: 1055-9965            page 659, left-hand column, paragraph 2 - paragraph 3            page 659, right-hand column, paragraph 7            -page 660, left-hand column, paragraph 1            page 663, right-hand column, last paragraph            page 664, left-hand column, paragraph 2</p> <p>---</p>	2,4-7, 9-13
Y	<p>ADJEI A A: "EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN CANCER THERAPY"            DRUGS OF THE FUTURE, BARCELONA, ES,            vol. 26, no. 1, 2001, pages 1087-1092, XP001062438            ISSN: 0377-8282            page 1088, left-hand column, paragraph 3            -right-hand column, paragraph 1            page 1091, left-hand column, paragraph 2            figures 1,2</p> <p>---</p>	2,4-7, 9-13
A	<p>WO 97 27199 A (CIBA GEIGY AG ;TRAXLER PETER (CH); FREI JOERG (CH); BOLD GUIDO (CH) 31 July 1997 (1997-07-31)            cited in the application            the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	1,4-7, 9-12

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/12024

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 39121 A (FIDLER ISAIAH J ;UNIV TEXAS (US); BUCANA CORAZON D (US)) 16 May 2002 (2002-05-16) page 1, line 25 -page 2, line 1 page 4, line 4 - line 7 page 5, line 17 - line 27 claims 19,20,25-29	1,2,4-7, 9-13
P,X	& US 2002/132275 A1 19 September 2002 (2002-09-19) claims 19,25-29 ---	
P,X	WO 02 067941 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); TRAXLER PETER (CH)) 6 September 2002 (2002-09-06) page 3, paragraph 3 page 4, paragraph 3 page 10, paragraph 3 claims 1,7,8 ---	1,2,4-7, 9-13
P,X	WO 02 41882 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); TRAXLER PETER (CH)) 30 May 2002 (2002-05-30) page 6, paragraph 3 page 16, paragraph 3 -page 17, paragraph 1 claims 7,11-13 ---	1,2,4-7, 9-13
P,X	BAKER CHERYL H ET AL: "Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas." AMERICAN JOURNAL OF PATHOLOGY. UNITED STATES SEP 2002, vol. 161, no. 3, September 2002 (2002-09), pages 929-938, XP008014432 ISSN: 0002-9440 abstract page 934, left-hand column, paragraph 3 -right-hand column, paragraph 1 page 938, right-hand column, paragraph 1 table 2 -----	1,2,4-7, 9-13

# INTERNATIONAL SEARCH REPORT

national application No.  
PCT/EP 02/12024

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 4-7, and 9-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1, 2, 4-7, 9-13 (all partially)

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

The expression '7H-pyrrolo[2,3-d]pyrimidine derivative' in claims 1, 4-7, and 9-12 is considered to be unclear as neither the nature of derivatisation nor its extent has been defined.

The search has been restricted to the use of those 7H-pyrrolo[2,3-d]pyrimidines which appear to be clear, supported, and relating to the first invention, namely to the use of the 7H-pyrrolo[2,3-d]pyrimidine PKI 166 in the treatment of carcinoma of the bladder.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of carcinomas of the bladder, and for the prevention of their metastatic growth.

2. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of renal carcinomas, and for the prevention of their metastatic growth.

3. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of squamous cell carcinomas of the skin, and for the prevention of their metastatic growth.

4. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of head and neck cancers, including squamous cell head and neck cancer, as far as not part of invention 3, and for the prevention of their metastatic growth.

5. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of lung cancers, including non-small cell lung cancer (NSCLC), and for the prevention of their metastatic growth.

6. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

o[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of tumors of the gastrointestinal tract, and for the prevention of their metastatic growth.

## 7. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo  
o[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of gliomas, and for the prevention of their metastatic growth.

## 8. Claims: 1, 2, 4-7, 9-13 (all partially)

Use of  
(R)-6-(4-hydroxy-phenyl)-4-[(1-phenyl-ethyl)-amino]-7H-pyrrolo  
o[2,3-d]pyrimidine (PKI166) in the manufacture of a medicament for the treatment of mesotheliomas, and for the prevention of their metastatic growth.

## 9. Claims: claims 3, 8, 14, and partially 1, 4-7, 9-12

Use of 7H-pyrrolo[2,3-d]pyrimidines of formula (I), in the manufacture of a medicament for the treatment of carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, tumors of the gastrointestinal tract, mesothelioma, esophageal tumors, stomach cancer, small-bowel tumors, large-bowel tumors, including polyps of the colon and rectum, and anorectal cancer, and for the prevention of their metastatic growth.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12024

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9702266	A	23-01-1997	AT 212993 T	15-02-2002
			AU 707626 B2	15-07-1999
			AU 6414896 A	05-02-1997
			BR 9609617 A	25-05-1999
			CA 2224435 A1	23-01-1997
			CN 1194647 A ,B	30-09-1998
			CZ 9800015 A3	15-04-1998
			DE 69619114 D1	21-03-2002
			DE 69619114 T2	02-10-2002
			DK 836605 T3	13-05-2002
			EA 980116 A1	29-10-1998
			WO 9702266 A1	23-01-1997
			EP 0836605 A1	22-04-1998
			ES 2172670 T3	01-10-2002
			HU 9900330 A2	28-05-1999
			JP 11508570 T	27-07-1999
			NO 975956 A	10-02-1998
			NZ 312665 A	30-08-1999
			PL 324285 A1	11-05-1998
			PT 836605 T	31-07-2002
			SI 9620103 A	31-10-1998
			SK 398 A3	08-07-1998
			TR 9800012 T1	21-04-1998
			TW 472057 B	11-01-2002
			US 6140332 A	31-10-2000
			ZA 9605723 A	06-01-1997
-----				
WO 0132155	A	10-05-2001	AU 1155901 A	14-05-2001
			BR 0015194 A	18-06-2002
			CA 2389411 A1	10-05-2001
			CN 1387437 T	25-12-2002
			EP 1272188 A2	08-01-2003
			WO 0132155 A2	10-05-2001
			JP 2003513035 T	08-04-2003
			NO 20022065 A	24-06-2002
-----				
WO 9727199	A	31-07-1997	AT 217873 T	15-06-2002
			AU 1441497 A	20-08-1997
			CA 2242354 A1	31-07-1997
			DE 69712745 D1	27-06-2002
			DE 69712745 T2	31-10-2002
			WO 9727199 A1	31-07-1997
			EP 0888349 A1	07-01-1999
			ES 2177925 T3	16-12-2002
			JP 2000503005 T	14-03-2000
			PT 888349 T	31-10-2002
			US 6140317 A	31-10-2000
-----				
WO 0239121	A	16-05-2002	AU 3657202 A	21-05-2002
			WO 0239121 A2	16-05-2002
			US 2002132275 A1	19-09-2002
-----				
WO 02067941	A	06-09-2002	WO 02067941 A2	06-09-2002
-----				
WO 0241882	A	30-05-2002	AU 2368402 A	03-06-2002
			WO 0241882 A2	30-05-2002
-----				